Abstract | BACKGROUND: OBJECTIVE: The present meta-analysis examined premature study discontinuation (PSD) and dose-response associated with ziprasidone. Furthermore, a systematic review of the clinical pharmacokinetic and pharmacodynamic properties and tolerability of ziprasidone was conducted to explain the meta-analytic findings. METHODS: A systematic search was performed in the electronic databases PubMed and EMBASE using the key words ziprasidone, randomized, positron emission tomography, pharmacokinetic, and tolerability. This search looked for open-label or blinded studies of oral ziprasidone use in patients with psychoses ( schizophrenia-spectrum disorders and/or bipolar mania) published between January 1, 1992, and February 1, 2011. Comparisons with antipsychotics for which there were <3 studies in total were excluded. PSD (all causes) was used as a measure of overall effectiveness. RESULTS: Thirty-one studies were included in the final analysis. The rates of PSD were significantly higher with ziprasidone compared with olanzapine (inefficacy and all causes, P < 0.001) and risperidone (all causes, P = 0.004). In contrast, the rates of PSD due to inefficacy and adverse events were significantly lower with ziprasidone compared with quetiapine (P = 0.03) and haloperidol (P = 0.03), respectively. On dose-response analysis, the rate of all-cause PSD was significantly lower with combined 120-160 mg/d compared with placebo (P = 0.001). Low levels of hyperprolactinemia and weight gain/metabolic adverse events, and moderate extrapyramidal symptoms and corrected QT-interval prolongation were reported with ziprasidone use. Ziprasidone exposure was increased when the medication was administered with food, irrespective of fat content. Ziprasidone 120-160 mg/d was correlated with 60% to 80% occupancy in studies of D(2) binding with the administration of multiple doses. However, the same occupancy was achieved with single-dose administration at much lower doses (20-60 mg/d). CONCLUSIONS:
|
Authors | Emmanuel Stip, Simon Zhornitsky, Hoda Moteshafi, Geneviève Létourneau, Irena Stikarovska, Stéphane Potvin, Valérie Tourjman |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 33
Issue 12
Pg. 1853-67
(Dec 2011)
ISSN: 1879-114X [Electronic] United States |
PMID | 22133697
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Copyright | Copyright © 2011 Elsevier HS Journals, Inc. All rights reserved. |
Chemical References |
- Antipsychotic Agents
- Dopamine Antagonists
- Dopamine D2 Receptor Antagonists
- Piperazines
- Receptors, Dopamine D2
- Thiazoles
- ziprasidone
|
Topics |
- Antipsychotic Agents
(administration & dosage, adverse effects, pharmacokinetics)
- Dopamine Antagonists
(administration & dosage, adverse effects, pharmacokinetics)
- Dopamine D2 Receptor Antagonists
- Dose-Response Relationship, Drug
- Evidence-Based Medicine
- Food-Drug Interactions
- Humans
- Patient Selection
- Piperazines
(administration & dosage, adverse effects, pharmacokinetics)
- Psychotic Disorders
(diagnosis, drug therapy, metabolism, psychology)
- Receptors, Dopamine D2
(metabolism)
- Risk Assessment
- Thiazoles
(administration & dosage, adverse effects, pharmacokinetics)
- Treatment Outcome
|